MedAI Verdict
Decision support

Clinical Decision Support

LU

Luminare

by Luminare  ·  founded 2014  ·  US

Last verified

EHR-integrated AI platform that detects sepsis risk and supports sepsis management for hospitals.

Visit Luminare (opens in new tab)Read our methodology

At a glance

Pricing
No public price.
HIPAA
Not disclosed
SOC 2
Not disclosed
EHRs
—
Founded
2014
HQ
US
On this page

Independent score  ·  By our public rubric

12/100Tracked

Not rated: too little independent evidence yet.

How it’s computed →
  • Regulatory & Compliance
    0/22

    No FDA clearance listed

  • Clinical Integration
    0/11.6

    No EHR integrations listed

  • Evidence Strength
    0/30

    No peer-reviewed coverage

  • Vendor & Market
    9/18

    Founded 2014 (12 years)

  • Sentiment & Transparency
    1.3/2.5

    Pricing on request, no public amounts

▸ Show all 11 dimensions

Regulatory & Compliance

  • FDA clearance0/12

    No FDA clearance listed

  • HIPAA / SOC2 / BAA0/10

    No public HIPAA/SOC2/BAA attestation

Clinical Integration

  • EHR integrations (count)0/6

    No EHR integrations listed

  • Top-3 EHR coverage (Epic / Oracle / Athena)0/5

    None of the top-3 EHRs covered

  • Bidirectional write-back0/1

    No bidirectional write-back documented

Evidence Strength

  • Peer-reviewed papers0/21

    No peer-reviewed coverage

  • RCT / meta-analysis / systematic review0/9

    No RCT, meta-analysis, or systematic review

Vendor & Market

  • Funding & adoption signal3/12

    Seed-stage or unfunded

  • Years in market6/6

    Founded 2014 (12 years)

Sentiment & Transparency

  • Pricing transparency1/3

    Pricing on request, no public amounts

Scored November 2, 2026 · Public scoring method v1.2.0

EHR-integrated AI platform that detects sepsis risk and supports sepsis management for hospitals.

No public price.

Evidence record

FDA decisions

No FDA decision cited in our research as of November 2, 2026.

Verification
  • Score computed November 2, 2026, method 1.2.0
  • Review written November 2, 2026
Cite this record

MedAI Verdict, Luminare record, https://medaiverdict.com/tools/luminare, version November 2, 2026

Change history
View every change to this record

Bottom line

Luminare, Inc. of Houston sells the Sepsis Care Platform, which it describes as EHR-integrated software that uses AI patient phenotyping to detect and manage sepsis. Sarma Velamuri and Marcus Rydberg founded it in 2014, per InnovationMap's July 2023 profile, and Crunchbase lists a seed-stage private company with 11 to 50 employees. Cedars-Sinai is the one hospital linked to it, through an accelerator. No FDA clearance is stated in the InnovationMap profile or the ACHE post.

What does the software do?

Luminare describes the Sepsis Care Platform as software that "integrates with existing EHR systems" and works with third-party virtual nursing platforms. InnovationMap reported on July 11, 2023 that it screens patients for sepsis risk "in 10 seconds using 50 parameters." In a sponsor-spotlight post on the ACHE SETC site, Luminare says its phenotyping system Emily was built on 3.5 million Mayo Clinic Platform records and offers treatment recommendations and less alert fatigue. The company also states a return on investment in 2 to 6 months and support for Medicare SEP-1 reporting and value-based purchasing.

Who is behind it, and how is it funded?

Luminare is based in the Texas Medical Center Innovation Factory in Houston, with part of the staff in Stockholm. Velamuri has been CEO full-time since 2017 and Rydberg is CTO. Seedtable lists $1.1 million on October 1, 2019 as the last known round, and neither Seedtable nor Crunchbase lists a later one. The ACHE post calls Luminare a graduate of Mayo Clinic Platform Accelerate, and InnovationMap reported that Cedars-Sinai uses the technology after Luminare joined its accelerator.

What does the literature say?

One PubMed paper carries a Luminare affiliation: Ferreira, McCants and Velamuri in the Journal of Healthcare Quality Research, 2023 (PMID 36319584). Titled "Using machine learning for process improvement in sepsis management," it reviews literature from January 2017 to February 2022, and the CEO is a co-author. It surveys machine-learning approaches to sepsis in general and reports no hospital result for Luminare's software, so it does not test the product.

The verdict

A hospital sepsis program willing to evaluate an early vendor would be working from Luminare's own claims, InnovationMap's "10 seconds using 50 parameters" line and an accelerator link to Cedars-Sinai and, per the ACHE post, a Mayo Clinic Platform Accelerate graduation. A hospital that requires an FDA-cleared product or a named EHR build is looking at other vendors.

Editorial review last generated November 2, 2026. Synthesized from clinician sentiment, peer-reviewed coverage, and our editorial silo picks. Refined by hand where vendor facts change.

What it costs

All tiers are custom-quoted. The vendor does not publish per-provider list pricing.

TierMonthlyAnnualNotes
EnterpriseNot statedNot statedNo public price.

Source: vendor pricing page. Last checked November 2, 2026.

Who builds it

Luminare (Luminare) was founded in 2014 in US, putting it 12 years into market.

Other decision support

See the full decision support ranking